Y0000472
Cabergoline
European Pharmacopoeia (EP) Reference Standard
同義詞:
1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea, 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, Cabaser, Dostinex, FCE-21336
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C26H37N5O2
CAS號碼:
分子量：:
451.60
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推薦產品
等級
pharmaceutical primary standard
API 家族
cabergoline
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
−20°C
SMILES 字串
CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1
InChI
1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
InChI 密鑰
KORNTPPJEAJQIU-KJXAQDMKSA-N
基因資訊
human ... DRD2(1813)
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Cabergoline EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Lact.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Annamaria Colao et al.
Nature clinical practice. Endocrinology & metabolism, 2(4), 200-210 (2006-08-26)
Prolactinoma is the most frequent pituitary tumor histotype. Men generally have macroadenomas whereas women generally have microadenomas. The major objectives of treating prolactinomas are to suppress excessive hormone secretion and its clinical consequences, to remove the tumor mass while preserving
Chiara Bianca Maria Platania et al.
Biochemical pharmacology, 86(9), 1347-1356 (2013-08-22)
Elevated intraocular pressure (IOP) is the main recognized risk factor of glaucoma. To investigate the contribution of dopaminergic and serotonergic systems in IOP regulation, we used cabergoline, a mixed dopamine and serotonin agonist, in C57BL/6J WT and dopamine D₃ receptor
M C Porter et al.
International journal of clinical practice, 56(6), 468-474 (2002-08-09)
Dopamine agonists have diverse chemical and physical properties that can directly stimulate the dopamine receptors, unlike levodopa which undergoes presynaptic breakdown to dopamine before dopaminergic effects in Parkinson's disease (PD). Cabergoline, a dopamine agonist effective given once daily, is being
F Bogazzi et al.
Journal of endocrinological investigation, 31(12), 1119-1123 (2009-02-28)
Dopamine agonists have been associated with increased risk of cardiac valve regurgitation in patients with Parkinson's disease. Whether these drugs might be harmful for patients with hyperprolactinemia is still unsettled. Occasional case reports and 7 studies on the relationship between
Renata S Auriemma et al.
European journal of endocrinology, 169(3), 359-366 (2013-07-05)
Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve regurgitation in Parkinson's disease, whereas several retrospective analyses failed to detect a similar relation in hyperprolactinemic patients. The current study aimed at investigating cardiac valve disease
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務